AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company that entered the public markets through its de-SPAC merger with Priveterra Acquisition Corp., a blank-check vehicle that completed its IPO in 2021 with Priveterra Sponsor, LLC serving as sponsor. Operating in the healthcare and life sciences sector, AEON is focused on developing proprietary formulations of botulinum toxin complex for therapeutic indications. The company continues to file as an active reporting issuer with the SEC, most recently submitting a Form 8-K current report on May 14, 2026. For comprehensive SPAC deal history, filing timelines, and deep-dive analytics on AEON and thousands of other transactions, sign up for full data access at SpacDesk.